{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:27:04Z","timestamp":1786678024849,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26K19315"],"award-info":[{"award-number":["JP26K19315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtocrr.2026.101020","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T06:55:22Z","timestamp":1779260122000},"page":"101020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-1995","authenticated-orcid":false,"given":"Yasuhiro","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Shirakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwako","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Fukuizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakeru","family":"Hisakane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakamichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Miyanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101020_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2026.101020_bib2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib4","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2026.101020_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib8","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.2217\/fon-2021-0904","article-title":"Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer","volume":"17","author":"Solomon","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2026.101020_bib11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib12","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.3390\/cancers12123608","article-title":"Efficacy of dabrafenib plus trametinib combination in patients with BRAF V600E-mutant NSCLC in real-world setting: GFPC 01-2019","volume":"12","author":"Auliac","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2026.101020_bib13","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET Exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib14","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101020_bib18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtocrr.2026.101020_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global Phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtocrr.2026.101020_bib21","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/cas.13977","article-title":"Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan","volume":"110","author":"Masuda","year":"2019","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtocrr.2026.101020_bib22","article-title":"Real-world comparative effectiveness of first-line alectinib versus crizotinib in patients with advanced ALK-positive NSCLC with or without baseline central nervous system metastases","volume":"4","author":"Zhang","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2026.101020_bib23","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/fon-2021-1102","article-title":"Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108478","article-title":"Real-world safety and effectiveness of entrectinib in Japanese patients with ROS1 gene fusion-positive, unresectable, advanced\/recurrent non-small cell lung cancer: post-marketing surveillance","volume":"203","author":"Seto","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101020_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jtho.2024.12.010","article-title":"Actionable NSCLC mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European program for the routine testing of patients with advanced lung cancer (EPROPA)","volume":"20","author":"Passiglia","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib26","article-title":"Real-world survival outcomes in non-small cell lung cancer: the impact of genomic testing and targeted therapies in a Latin American middle-income country","volume":"10","author":"Hernandez-Martinez","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib27","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101020_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113556","article-title":"First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations","volume":"199","author":"Blasi","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2026.101020_bib29","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1158\/1078-0432.CCR-25-1735","article-title":"First-Line MET tyrosine kinase Inhibitors versus Immunotherapy \u00b1 Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101020_bib30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jtho.2025.04.016","article-title":"Treatment sequences in BRAF-V600-Mutated NSCLC: first-line targeted therapy versus first-line (chemo-) immunotherapy","volume":"20","author":"Wiesweg","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib31","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2026.101020_bib32","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1556-0864(25)00280-1","article-title":"85P: phase I results from the phase I\/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC)","volume":"20","author":"Koster","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jtho.2025.01.006","article-title":"A single-arm Phase 2 study of sotorasib plus carboplatin and pemetrexed in patients with advanced nonsquamous NSCLC with KRAS G12C mutation (WJOG14821L, Scarlet)","volume":"20","author":"Akamatsu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101020_bib34","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p. G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T02:34:00Z","timestamp":1786674840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666364326000718"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101020","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Treatment Outcomes Across Actionable Genomic Alterations in NSCLC: A Large Multicenter Real-World Study","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101020"}}